Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in CRISPR Therapeutics AG, Intellia Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how CRISPR Therapeutics AG, Intellia Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About CRISPR Therapeutics AG, Intellia Therapeutics and Inc.

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company’s lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient’s hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company’s in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Latest Biotechnology and CRISPR Therapeutics AG, Intellia Therapeutics, Inc. Stock News

As of May 29, 2026, CRISPR Therapeutics AG had a $5.4 billion market capitalization, compared to the Biotechnology median of $280.8 million. CRISPR Therapeutics AG’s stock is up 3.3% in 2026, up 7.6% in the previous five trading days and up 50.92% in the past year.

Currently, CRISPR Therapeutics AG does not have a price-earnings ratio. CRISPR Therapeutics AG’s trailing 12-month revenue is $4.1 million with a % net profit margin. Year-over-year quarterly sales growth most recently was 66.7%. Analysts expect adjusted earnings to reach $-4.788 per share for the current fiscal year. CRISPR Therapeutics AG does not currently pay a dividend.

As of May 29, 2026, Intellia Therapeutics, Inc. had a $2.0 billion market cap, putting it in the 54th percentile of all stocks. Intellia Therapeutics, Inc.’s stock is up 52.7% in 2026, up 9% in the previous five trading days and up 45.65% in the past year.

Currently, Intellia Therapeutics, Inc. does not have a price-earnings ratio. Intellia Therapeutics, Inc.’s trailing 12-month revenue is $66.1 million with a -597.0% net profit margin. Year-over-year quarterly sales growth most recently was -9.6%. Analysts expect adjusted earnings to reach $-3.164 per share for the current fiscal year. Intellia Therapeutics, Inc. does not currently pay a dividend.

How We Compare CRISPR Therapeutics AG, Intellia Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at CRISPR Therapeutics AG, Intellia Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

CRISPR Therapeutics AG, Intellia Therapeutics and Inc. Stock Value Grades

Company	Ticker	Value
CRISPR Therapeutics AG	CRSP	na
Intellia Therapeutics, Inc.	NTLA	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

CRISPR Therapeutics AG does not have a meaningful Value Score. Intellia Therapeutics, Inc. has a Value Score of 10, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither CRISPR Therapeutics AG, Intellia Therapeutics or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if CRISPR Therapeutics AG, Intellia Therapeutics or Inc. is the better investment when it comes to value.

CRISPR Therapeutics AG, Intellia Therapeutics and Inc. Growth Grades

Company	Ticker	Growth
CRISPR Therapeutics AG	CRSP	F
Intellia Therapeutics, Inc.	NTLA	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

CRISPR Therapeutics AG has a Growth Score of 7, which is Very Weak. Intellia Therapeutics, Inc. has a Growth Score of 17, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither CRISPR Therapeutics AG, Intellia Therapeutics or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if CRISPR Therapeutics AG, Intellia Therapeutics or Inc. is the better investment when it comes to sustainable growth.

CRISPR Therapeutics AG, Intellia Therapeutics and Inc.’s Quality Grades

Company	Ticker	Quality
CRISPR Therapeutics AG	CRSP	F
Intellia Therapeutics, Inc.	NTLA	D

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

CRISPR Therapeutics AG has a Quality Score of 11, which is Very Weak. Intellia Therapeutics, Inc. has a Quality Score of 25, which is Weak.

The Quality Stock Winner: No Clear Winner

Neither CRISPR Therapeutics AG, Intellia Therapeutics or Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if CRISPR Therapeutics AG, Intellia Therapeutics or Inc. is the better investment when it comes to quality.

Other CRISPR Therapeutics AG, Intellia Therapeutics and Inc. Grades

In addition to Quality, Value and Growth, A+ Investor also provides grades for Momentum and Estimate Revisions.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether CRISPR Therapeutics AG, Intellia Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, CRISPR Therapeutics AG, Intellia Therapeutics or Inc. Stock?

Overall, CRISPR Therapeutics AG stock has a Value Score of , Growth Score of 7 and Quality Score of 11.

Intellia Therapeutics, Inc. stock has a Value Score of 10, Growth Score of 17 and Quality Score of 25.

Comparing CRISPR Therapeutics AG, Intellia Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.